Baidu
map

血液科

订阅

MedSci主页 / 所有栏目 / 血液科

ASH 2014：中高危MDS和CMML的临床难题仍待探索

2014-12-22 CMT 中国医学论坛报

ASH血液病白血病
关注

北京协和医院血液科庄俊玲副教授应记者邀请对当地时间12月9日上午ASH2014公布的一项关于中高危骨髓异常增生综合征(MDS)和慢性粒单核细胞白血病">白血病(CMML)的最新揭晓临床研究(LBA)给予了解读。 Sekeres M.A.等代表北美协作组多家单位，将SWOG S1117方案的初步结果(摘要号：LBA-5)在今年ASH会议上汇报。这项Ⅱ期随机临床试验比较了去甲基化药物阿扎胞

北京协和医院血液科庄俊玲副教授应记者邀请对当地时间12月9日上午ASH2014公布的一项关于中高危骨髓异常增生综合征(MDS)和慢性粒单核细胞白血病">白血病(CMML)的最新揭晓临床研究(LBA)给予了解读。

Sekeres M.A.等代表北美协作组多家单位，将SWOG S1117方案的初步结果(摘要号：LBA-5)在今年ASH会议上汇报。这项Ⅱ期随机临床试验比较了去甲基化药物阿扎胞苷(AZA)联合来那度胺(LEN)或组蛋白去乙酰化酶抑制剂(HDACI)伏林司他(VOR)与阿扎胞苷单药治疗中高危骨髓异常增生综合征(MDS)和慢性粒单核细胞白血病(CMML)患者的疗效和安全性。研究共入组282例患者，中位随访9个月，中位用药时间为23周，各组近似。全部队列的总有效率(ORR)为33%，AZA组36%，AZA+LEN组37%，AZA+VOR组22%(p=0.07)。所有患者中位无复发时间(RFS)为7个月。不良反应包括粒细胞减少，消化道反应和感染在各组类似。

北京协和医院血液科庄俊玲教授：中高危MDS和CMML，尤其是伴有原始细胞增多的患者，向白血病转化的发生率高，常规化疗效果差，生存期缩短，是临床面对的难题。异基因造血干细胞移植是唯一可能治愈此类疾患的方法，近几年研究发现去甲基化药物也有一定疗效，但联合HDACI或免疫调剂剂(IMiD)是否具有协同作用是本研究所回答的问题。研究结果发现不管是ORR还是RFS在单药或联合用药组均无显著差异， AZA+LEN治疗后中性粒细胞升高虽然显著好于其他两组，但总体疗效并未改善。所有患者用药7个月左右出现疾病进展，少数接受异基因干细胞移植，再次说明疾病预后不佳。本研究的阴性结果尚不能完全否定联合用药的疗效，可能需要随访更长时间才能得出确切结论。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1842782, encodeId=098d1842e82ff, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11422, encryptionId=9f061142249, topicName=MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sat Dec 27 20:17:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685406, encodeId=cf3e16854066d, content=<a href='/topic/show?id=7c5c490342' target=_blank style='color:#2F92EE;'>#CMML#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4903, encryptionId=7c5c490342, topicName=CMML)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c7c28182882, createdName=kkunny, createdTime=Tue Jul 28 06:17:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822234, encodeId=d1571822234fa, content=<a href='/topic/show?id=c6071022467a' target=_blank style='color:#2F92EE;'>#高危MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102246, encryptionId=c6071022467a, topicName=高危MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 02 23:17:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17551, encodeId=2e111e55156, content=超赞，好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Wed Mar 04 10:47:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301151, encodeId=060f130115144, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=)]
    2014-12-27 d830372

    #MDS#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1842782, encodeId=098d1842e82ff, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11422, encryptionId=9f061142249, topicName=MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sat Dec 27 20:17:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685406, encodeId=cf3e16854066d, content=<a href='/topic/show?id=7c5c490342' target=_blank style='color:#2F92EE;'>#CMML#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4903, encryptionId=7c5c490342, topicName=CMML)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c7c28182882, createdName=kkunny, createdTime=Tue Jul 28 06:17:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822234, encodeId=d1571822234fa, content=<a href='/topic/show?id=c6071022467a' target=_blank style='color:#2F92EE;'>#高危MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102246, encryptionId=c6071022467a, topicName=高危MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 02 23:17:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17551, encodeId=2e111e55156, content=超赞，好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Wed Mar 04 10:47:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301151, encodeId=060f130115144, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=)]
    2015-07-28 kkunny

    #CMML#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1842782, encodeId=098d1842e82ff, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11422, encryptionId=9f061142249, topicName=MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sat Dec 27 20:17:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685406, encodeId=cf3e16854066d, content=<a href='/topic/show?id=7c5c490342' target=_blank style='color:#2F92EE;'>#CMML#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4903, encryptionId=7c5c490342, topicName=CMML)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c7c28182882, createdName=kkunny, createdTime=Tue Jul 28 06:17:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822234, encodeId=d1571822234fa, content=<a href='/topic/show?id=c6071022467a' target=_blank style='color:#2F92EE;'>#高危MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102246, encryptionId=c6071022467a, topicName=高危MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 02 23:17:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17551, encodeId=2e111e55156, content=超赞，好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Wed Mar 04 10:47:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301151, encodeId=060f130115144, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=)]
    2015-03-02 hbwxf

    #高危MDS#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1842782, encodeId=098d1842e82ff, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11422, encryptionId=9f061142249, topicName=MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sat Dec 27 20:17:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685406, encodeId=cf3e16854066d, content=<a href='/topic/show?id=7c5c490342' target=_blank style='color:#2F92EE;'>#CMML#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4903, encryptionId=7c5c490342, topicName=CMML)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c7c28182882, createdName=kkunny, createdTime=Tue Jul 28 06:17:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822234, encodeId=d1571822234fa, content=<a href='/topic/show?id=c6071022467a' target=_blank style='color:#2F92EE;'>#高危MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102246, encryptionId=c6071022467a, topicName=高危MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 02 23:17:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17551, encodeId=2e111e55156, content=超赞，好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Wed Mar 04 10:47:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301151, encodeId=060f130115144, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=)]
    2015-03-04 xiaoai5777

    超赞，好文章

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1842782, encodeId=098d1842e82ff, content=<a href='/topic/show?id=9f061142249' target=_blank style='color:#2F92EE;'>#MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11422, encryptionId=9f061142249, topicName=MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sat Dec 27 20:17:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1685406, encodeId=cf3e16854066d, content=<a href='/topic/show?id=7c5c490342' target=_blank style='color:#2F92EE;'>#CMML#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4903, encryptionId=7c5c490342, topicName=CMML)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5c7c28182882, createdName=kkunny, createdTime=Tue Jul 28 06:17:00 CST 2015, time=2015-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822234, encodeId=d1571822234fa, content=<a href='/topic/show?id=c6071022467a' target=_blank style='color:#2F92EE;'>#高危MDS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102246, encryptionId=c6071022467a, topicName=高危MDS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Mar 02 23:17:00 CST 2015, time=2015-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=17551, encodeId=2e111e55156, content=超赞，好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=36a81612921, createdName=xiaoai5777, createdTime=Wed Mar 04 10:47:00 CST 2015, time=2015-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301151, encodeId=060f130115144, content=<a href='/topic/show?id=38e32852fe' target=_blank style='color:#2F92EE;'>#ASH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2852, encryptionId=38e32852fe, topicName=ASH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=39a0295, createdName=kksonne, createdTime=Wed Dec 24 00:17:00 CST 2014, time=2014-12-24, status=1, ipAttribution=)]
    2014-12-24 kksonne

    #ASH#

    0

相关资讯

ASH 2014：HSCT后单纯性持续性血小板减少症机制

异基因造血干细胞移植是根治恶性血液病等严重危害人类健康的疾病的重要手段。单纯性持续性血小板减少症是移植后影响患者长期生存的重要的合并症。其发病机制多年来一直未有突破性进展。本课题组系列的原创性的研究工作得到了美国血液学会(ASH)年会专家的邀请，并在本次年会做大会口头报告。 北京大学血液病研究所在2014年ASH年会上共有3个口头报告，是北京大学血液病研究所数量最多的一次。 ——北京大学人民医

ASH 2014：osaroxin+阿糖胞苷改善复发性AML患者的生存

Vosaroxin+阿糖胞苷(Ara-C)对比安慰剂+Ara-C改善了复发/难治急性髓性白血病">白血病(AML)患者的生存 ：Ⅲ期双盲随机对照多中心研究(VALOR研究) 北京大学人民医院、北京大学血液病研究所 江浩 难治/复发AML的治疗40年来无重大突破，此届ASH公布了新型制剂vosaroxin联合Ara-C的研究数据，以更多的病例数据证实了可提高此群患者的疗效和生存，尤其在老年

ASH 2014：NovoEight®可减轻高基线A型血友病出血

2014年第56届美国血液学会年会（ASH）于12月6日-9日在美国旧金山举行。会上公布了A型血液病药物NovoEight®（turoctocog alpha，重组凝血因子VIII）III期Guardian项目新的分析数据。Guardian-TM1研究显示，NovoEight初始治疗时年平均出血率（ABR）最高的A型血友病患者群体，在治疗持续期间出血次数表现出最大幅度的降低。Guardian-TM

ASH 2014：癌症治疗价格日益攀升的伦理问题

不要迁怒于信使 在美国，约20%的国内生产总值被用于医疗卫生领域，其中5%用于癌症治疗。随着越来越多的人被诊断为癌症，进入市场的化疗药物数量呈现指数型增加，化疗费用也是如此。2012年，美国食品药品监督局批准了三种治疗慢性骨髓性白血病">白血病（CML）的新药物，这三种药物的每年费用达一百万美元，将近是2001年伊马替尼（格列卫）的5倍。被转嫁给患者的部分费用日益增加，导致严重的“经济毒性

ASH 2014：CAR-T免疫疗法治疗难治性ALL缓解率达92%

2014年第56届美国血液学会年会（ASH）于12月6日-9日在美国旧金山举行。会上公布了深受业界期待的CAR-T免疫疗法CTL019的最新临床数据，在这些研究中，CTL019在某些类型淋巴细胞白血病">白血病表现出了巨大的治疗潜力。此次公布的一项长期儿科研究中，39例复发/难治（r/r）急性淋巴细胞白血病（ALL）儿科患者接受了CTL019的治疗，数据显示，有36例患者经历了完全缓解（CR

ASH 2014：儿童ALL的基因组分析研究

过去半个世纪医学界最伟大的成就之一是儿童急性淋巴细胞性白血病">白血病（ALL）治疗实现了将近90%的无事件生存率。虽然取得了这样的成绩，ALL依然是儿童癌症相关死亡的主要致病因。在我们致力研究进一步提高ALL和其它癌症治疗的进程中，癌症基因学的前沿领域为我们提供了巨大潜力。本次教育项目会议“洞察儿童恶性血液病：以急性淋巴细胞性白血病为重点”将提供有关儿童ALL的最新讯息，讨论该领域的最新进

Baidu
map
Baidu
map
Baidu
map